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Background: Latent membrane protein (LMP) 1 and LMP2A encoded by Epstein-Barr virus (EBV) are associated
with the development of malignancies, but their expression in extranodal NK/T-cell lymphoma, nasal type (ENKTL)
and the relationship with clinical characteristics of this disease remain poorly understood. In the present study, we
examined the expression of LMP1 and LMP2A in ENKTL, and investigated the correlations between LMP1 and
LMP2A expression with clinicopathological characteristics of ENKTL patients.
Methods: Paraffin sections of surgically removed samples from 16 ENKTL patients were analyzed by
immunohistochemistry and the related clinicopathological data were collected and analyzed.
Results: Elevated expression (immunohistochemistry score ≥ 4) of LMP1 and LMP2A was detected in the tumor
cells of ENKTL. High LMP1 expression was associated with positive B symptoms (p = 0.012), while high LMP2A
expression was related to gender (p = 0.029). The expression of both LMP1 and LMP2A showed significant
correlations with patients’ overall survival (p = 0.049, p = 0.036).
Conclusion: LMP1 and LMP2A may be prognostic indicators of survival in patients with ENKTL.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2443352538545899
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Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is
recognized as a distinct clinical pathological entity of
non-Hodgkin’s lymphoma, and develops more frequently
in East Asia and Central America than in the West [1,2].
ENKTL was previously described as lethal midline granu-
loma or midline reticulosis, which most commonly invades
the nasal cavity and other mucosal sites of the upper aero-
digestive tract. Although ENKTL can be diagnosed at early
stage, it is characterized by a strongly aggressive lymphoma* Correspondence: xujiaren@tom.com; xulinfeng@medmail.com.cn;
renjiechenent@yahoo.com.cn
6Department of Hematology and Oncology, Jiangsu Provincial Hospital,
No.65 Jiangsu Road, Nanjing 210029, China
7Department of General Surgery, The Second Affiliated Hospital of Nanjing
Medical University, No.121 Jiang jia yuan, Nanjing 210011, China
2Department of Otolaryngology-Head and Neck Surgery, The Second
Affiliated Hospital of Nanjing Medical University, No.121 Jiang jia yuan,
Nanjing 210011, China
Full list of author information is available at the end of the article
© 2012 Mao et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin advanced stage and resistance to different treatments
[3]. Currently, ENKTL is mainly treated by concurrent che-
moradiotherapy [4-6], but the overall survival is frustrat-
ingly poor [7]. Among the risk factors of ENKTL
development, Epstein-Barr virus (EBV) latent infection has
been shown to play an important role, and ENKTL is
closely associated with EBV infection [8-11].
EBV is a member of the g-herpes- virus family which
approximately infects 90% of the adult population in the
world. A variety of molecules are involved in EBV latent
infection, including EBV-encoded nuclear antigens
(EBNAs); EBNA leader protein (EBNA-LP); latent mem-
brane protein (LMP) 1, LMP2A, and LMP2B; and EBV
encoded RNAs (EBERs) EBER1 and EBER2 [12]. Among
these, LMP1 is essential for EBV-mediated growth trans-
formation of infected cells, and the C-terminal region of
LMP1 protein can regulate a variety of cellular signaling
pathways such as TNF receptor, NF-κB and JAK/STATd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion of lymphoma cells [13-15]. Therefore, LMP1 has
been suggested to have oncogenic effects in the develop-
ment and progression of EBV-related lymphomas. On
the other hand, LMP2A is one of the most commonly
present EBV encoding proteins and is widely expressed
in EBV-infected cells within the infected human host
and EBV-associated malignancies. LMP2A is the only
one membrane protein expressed in the reservoir of cir-
culating, latently EBV-infected resting B-cells [16].
LMP2A contributes to malignant transformation by
intervening with multiple signaling pathways, especially
the cell cycle and apoptotic pathways, thus plays import-
ant role in viral latency and tumorigenesis [17,18]. The
ability of LMP2A to influence the balance of survival factors
in B lymphocytes could be functionally important in Burkitt
lymphoma and LMP2A expression in EBV-infected B cells
may lead to the induction and maintenance of an activated,
proliferative state that could ultimately result in the devel-
opment of Hodgkin lymphoma [19,20]. However, the cor-
relation between the expression of LMP1 and LMP2A in
ENKTL and patient prognosis is poorly understood.
In this study, we examined the expression profiles of
LMP1 and LMP2A in ENKTL patients by immunohisto-












1 36 M Nasal cavity II Normal Positive LI
2 36 M Oropharynx III High Positive HI
3 57 M Nasal cavity II Normal Negative HI
4 55 M Larynx I Normal Positive LI
5 49 F Nasal cavity II High Negative L
6 51 M Nasal cavity I High Negative LI
7 67 M Nasal cavity II Normal Positive HI
8 25 M Oropharynx,
palate
II Normal Negative L
9 71 M Nasal cavity I High Positive LI
10 36 M Nasal cavity II Normal Negative L
11 63 M Nasal cavity I Normal Negative L
12 56 M Nasal cavity II Normal Positive LI
13 66 F Larynx II High Positive HI
14 47 M Nasopharynx I Normal Negative L
15 51 F Nasal cavity III Normal Positive HI
16 27 M Nasal cavity II Normal Negative LI
LDH: lactate dehydrogenase; IPI: international prognostic index; IHS: immunohistoch
protein 2A; L: low risk; LI: low-intermiediate risk; HI: high-intermiediate risk; CR: com
cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; FLAG: fludarabine, ar
dexamethasone, cisplatin; CVAD: cyclophosphamide, vindesine sulfate, adriamycin,
etoposide; ICE: ifosfamide, cisplatin, etoposide; SMILE: steroid, methotrexate, ifosfam
prednisone; VEPA: vincristine, cyclophosphamide, doxorubicin, predonisolone; DICEof LMP1 and LMP2A expression with the clinicopatholo-
gic features and outcomes of ENKTL. Our results suggest
that LMP1 and LMP2A are potential biomarkers for the
diagnosis and prognosis of patients with ENKTL.
Materials and methods
Patients and diagnosis
Total 16 cases of ENKTL were enrolled in this study
who were diagnosed at Department of Pathology, the
Affiliated Hospital of Nantong University between 2005
to 2011. All 16 cases were histologically confirmed, with
complete clinical information and follow-up data. The
pathologic diagnosis and classification of ENKTL was
based on the criteria described previously [1,21]: 1)
current World Health Organization classification; 2) the
histologic characteristics of ENKTL; 3) EBER expression
by in situ hybridization; 4) the expression of CD3 (T cell
markers) and CD56 by immunohistochemistry; 5) the
absence of B cell phenotype with CD20. Cases which
were negative for CD56 while positive for both cytotoxic
markers and EBER were also categorized as ENKTL.
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images. Study protocol was approved by the Ethics









CHOP + FLAG PR 6 6
CHOP PR 4 2
Surgery + CHOP CR 2 1
Surgery + CHOP PR 8 1
Surgery NR 1 4
CHOP + Radiotherapy PR 2 1
CHOP + GDP + CVAD CR 9 4
CHOPE + ICE + Radiotherapy CR 1 9
CHOP + SMILE CR 4 2
CHOP PR 6 1
CEVP + Radiotherapy PR 2 1
Surgery + CHOP PR 3 2
Surgery CR 6 8
VEPA + Radiotherapy CR 8 1
DICE + SMILE PR 9 9
Surgery + CHOP CR 3 6
emistry score; LMP1: latent membrane protein 1; LMP2A: latent membrane
plete remission; PR: partial remission; NR: no response; CHOP:
abinosylcytosine, granulocyte colony-stimulating factor; GDP: gemcitabine,
cisplatin; CHOPE: cyclophosphamide, hydroxydaunomycin, oncovin, prednisone,
ide, l-asparaginase, etoposide; CEVP: cyclophosphamide, epirubicin, vincristine,
: dexamethasone, ifosfamide, cisplatin, etoposide.
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Clinical data of 16 cases were obtained from hospital
medical records, which included age distribution, pa-
tient sex ratio, initial symptoms and signs, primary
sites, Ann Arbor stage, lactate dehydrogenase (LDH)
level, the presence of B symptoms, international prog-
nostic index (IPI), therapy strategies (surgery, chemo-
therapy or radiotherapy), response to treatment and
survival status.Histologic analysis
ENKTL tissue sections were formalin fixed, paraffin-
embedded and H&E-stained. The histopathological fea-
tures of the cases were evaluated independently by two
investigators.Figure 1 Immunohistochemical staining of LMP1 and LMP2A in clinic
of ENKTL tissue samples. (B1 and B2) Negative immunohistochemical stain
immunostaining of LMP1 in ENKTL tissue samples. (D1 and D2) Strong imm
immunostaining of LMP2A in ENKTL tissue samples. (F1 and F2) Strong im
magnification × 200 in A1, B1, C1, D1, E1 and F1; ×400 in A2, B2, C2, D2, E2In situ hybridization
EBERs in situ hybridization was performed on
formalin-fixed paraffin-embedded tissue sections on 3-
aminopropyltriethoxy-silane (Sigma, St. Louis, MO,
USA) treated slides using fluorescein isothiocyanate-
conjugated EBERs oligonucleotides as probes. Evaluation
of hybridized sites was detected by anti-fluorescein iso-
thiocyanate antibody labeled with alkaline phosphatase
(Dako, Cytomation, Glostrup, Denmark), according to
the manufacturer’s protocols. The control procedures, in-
cluding positive and negative control sections, were con-
ducted simultaneously.
Immunohistochemistry
Paraffin tissue sections were deparaffinized in 100% xy-
lene and rehydrated in graded ethanol solutions. Afteral tissue samples of ENKTL. (A1 and A2) Hematoxylin-eosin staining
ing of adjacent nontumorous tissue. (C1 and C2) Weak
unostaining of LMP1 in ENKTL tissue samples. (E1 and E2) Weak
munostaining of LMP2A in ENKTL tissue samples. Original
and F2.
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hydrogen peroxide solution for 15 min to block en-
dogenous peroxidase activity. Nonspecific binding was
blocked by incubation with 5% goat serum in TBS for
30 min. Tissue sections were then incubated with mono-
clonal antibodies anti-CD3 (Novocastra, Newcastle, UK),
anti-CD20 (Dako), anti-CD56 (Dako), anti-TIA-1
(Abcam, Cambridge, UK), anti-LMP1 (Abcam) and anti-
LMP2A (Abcam), followed by incubation with EnVision
horseradish peroxidase complex (DAKO). Negative con-
trols were included by the replacement of the primary
antibody with phosphate-buffered saline. Four fields in
each slide were randomly selected and counted, the per-
centage of positive staining was determined using immu-
nohistochemistry score (IHS) [22]. When a conclusion
differed, the final decision was made by consensus.
Results were analyzed according to the method
described previously [23]. Briefly, IHS was determined
by the evaluation of both staining density and intensity.Table 2 Association of LMP1 and LMP2A expression with clin
ENKTL
Groups No. LMP1 expression
Positive Negative
Gender
Male 13 7 6
Female 3 2 1
Age (years)
≤40 y 5 3 2
>40 y 11 6 5
Ann Arbor Stage
I-II 14 7 7
III-IV 2 2 0
LDH level
High 5 3 2
Normal 11 6 5
B symptoms
Positive 8 7 1
Negative 8 2 6
IPI
Low/Low-intermediate 11 5 6
High-intermediate/High 5 4 1
Response to treatment
Complete remission 7 4 3
Partial remission 8 5 3
No response 1 0 1
Prognosis
Live 7 2 5
Dead 9 7 2
LDH: lactate dehydrogenase; IPI: international prognostic index; LMP1: latent membThe percentage of positive tumor cells was scored as fol-
lows: 1 (0-10% positive cells), 2 (11-50% positive cells), 3
(51-80% positive cells), 4 (81-100% positive cells); and
the intensity of staining was scored as follows: 0 (nega-
tive), 1 (weakly positive), 2 (moderately positive), and 3
(strongly positive). Multiplication of the intensity and
the percentage scores gave rise to the ultimate immu-
noreactivity score: samples with a sum score below 3
(IHS ≤ 3) were judged as low protein expression, and
those with a sum score above 4 (IHS ≥ 4) as high protein
expression.
Statistical analysis
Statistical analyses were carried out by using STATA
Version 12.0 (Stata Corporation, College Station, TX)
and SPSS 18.0 statistic software (SPSS Inc, Chicago, IL).
The correlation of LMP1 and LMP2A expression with
clinicopathological features of ENKTL was analyzed by
chi-square test. Overall survival rate was estimated byical characteristics and selected biological markers of
p value LMP2A expression p value
Positive Negative
0.687 4 9 0.029*
3 0
0.838 3 2 0.377
4 7
0.182 6 8 0.849
1 1
0.838 2 3 0.838
5 6
0.012* 4 4 0.614
3 5
0.197 4 7 0.377
3 2
0.493 4 3 0.319
2 6
1 0
0.049* 1 6 0.036*
6 3
rane protein 1; LMP2A: latent membrane protein 2A; * P < 0.05.
Table 3 Survival analyses of prognostic factors in ENKTL
Variable p value
Gender
Male versus Female 0.0658
Age (years)
≤40y versus >40y 0.8679
Ann Arbor Stage
Stage I, II versus Stage III, IV 0.4129
LDH level
High versus Normal 0.7703
B symptoms
Positive versus Negative 0.0180*
IPI
L/LI versus HI/H 0.5418
Treatment
Single therapy versus Combined therapy 0.0082*
LMP1 expression
Positive versus Negative 0.0201*
LMP2A expression
Positive versus Negative 0.0487*
LDH: lactate dehydrogenase; IPI: international prognostic index.
L: low risk; LI: low-intermiediate risk; HI: high-intermiediate risk.
* P < 0.05.
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assessed by the log-rank test. P < 0.05 was considered as
statistical significance.
Results
Clinical features of ENKTL
The main clinicopathologic characteristics of patients
with ENKTL were shown in Table 1. All ENKTL
patients showed positive staining for CD3, TIA-1 and
EBER-1 and negative staining for CD20. CD56 expres-
sion was present in 43.8% of 16 cases. There was a pre-
ponderance of male to female patients with a ratio of
13:3. The median age at diagnosis was 49.6 years (range
25–71 years). Among the 16 cases, 11 were in the nasal
cavity, two in the oropharynx and/or palate, two in the
larynx, and one in nasopharynx. Nasal obstruction was
the most common initial symptom. According to the
Ann Arbor stage of lymphoma, five patients were in
stage I, nine in stage II and two in stage III of ENKTL.
Five patients showed high LDH expression, and eight
patients encountered B symptoms, including fever, night
sweats, and weight loss. Furthermore, the IPI was used
to predict the survival of patients with ENKTL. Most of
the patients (11 of 16) presented low to intermediate
risk, and the other five patients exhibited high to
intermediate risk. Of all 16 ENKTL patients, six pa-
tients received chemotherapy, four patients received a
combination of surgery and chemotherapy, four pa-
tients received a combination of chemotherapy and
radiotherapy, and two patients received surgery alone.
Seven patients experienced complete remission (CR)
(43.8%) and eight patients experienced partial remission
(PR) (50.0%), while one patient had no response (NR)
(6.2%).
Expression of LMP1 and LMP2A in ENKTL
LMP1 and LMP2A protein levels in ENKTL were exam-
ined using immunohistochemistry. High LMP1 expres-
sion was detected in nine (56.25%) of 16 ENKTL tissues
while high LMP2A expression was detected in seven
(43.75%) of 16 ENKTL tissues (Table 1). Typically
observed immunohistochemical staining patterns for
LMP1 and LMP2A were shown in Figure 1. For LMP1,
positive staining was mainly localized in the cell mem-
brane and cytoplasm, while for LMP2A, positive staining
was mostly located in the cytoplasm. No immunostain-
ing of LMP1 and LMP2A was observed in adjacent non-
tumorous tissues.
Correlation between LMP1 and LMP2A expression with
clinicopathological parameters of ENKTL
The relationship between LMP1 and LMP2A protein
levels with the clinicopathological parameters of 16
ENKTL patients was shown in Table 2. High LMP1expression was associated with positive B symptoms
(p = 0.012) and patients prognosis (0.049). No significant
association was found between LMP1 expression and
other clinical parameters, such as gender, age, Ann
Arbor stage, LDH level, IPI or response to treatment. In
contrast, high LMP2A expression was related to gender
(p = 0.029) and patients prognosis (0.036). No statistical
association was shown between LMP2A expression and
other clinical parameters, including age, Ann Arbor
stage, LDH level, B symptoms, IPI or response to treat-
ment (Table 2).
Patients’ survival
Kaplan-Meier analysis of 16 ENKTL patients showed
that the survival rate was significantly lower in patients
with positive B symptoms, subjected to single therapy,
or with high LMP1 and LMP2A expression. Log-rank
test showed that positive B symptoms, treatment by sin-
gle therapy, and high expression of LMP1 and LMP2A
were associated with decreased overall survival of
ENKTL patients (P = 0.0180, P = 0.0082, P = 0.0201, P =
0.0487) (Table 3, Figure 2).
Discussion
Most ENKTL cases show a uniform pattern of onset,
typical pleomorphic morphology, and a similar NK cell
immunophenotype. It is widely accepted that ENKTL is
Figure 2 Analysis of the survival of ENKTL patients by Kaplan-Meier method. (A) Overall survival rate in patients with positive B symptoms
(red line) was significantly lower than that in patients with negative B symptoms (green line). (B) Overall survival rate in patients with single
therapy (red line) was significantly lower than that in patients with combined therapy (green line). (C) Overall survival rate in patients with
positive LMP1 expression (red line) was significantly lower than that in patients with negative LMP1 expression (green line). (D) Overall survival
rate in patients with positive LMP2A expression (red line) was significantly lower than that in patients with negative LMP2A expression
(green line).
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pression of latent membrane protein products encoded
by EBV [8-11]. Among these protein products, LMP1 is
the most significant oncogenic protein which partici-
pates in the pathogenesis of EBV-associated lymphoma
and is essential for EBV-induced B-cell transformation
in vitro [12]. A variety of therapy strategies have been
developed to target LMP1 or interfere with its down-
stream signal pathway, such as NF-κB, MAPK/MEK/
ERK and JAK/STAT pathway, to inhibit tumor growth
[23-25]. LMP2A is generated by alternative splicing and
the expression of LMP2A in EBV-infected B cells may
lead to the induction and maintenance of an activated,
proliferative state that could ultimately result in the de-
velopment of EBV-related lymphoma [20]. LMP2A has
been utilized for targeted therapy and immunotherapyfor lymphoma [26-28]. However, the role of LMP1 and
LMP2A in ENKTL remains unclear.
In the present study, we examined the correlation of
LMP1 and LMP2A expression with clinical characteris-
tics of 16 ENKTL patients. The results showed that 56%
(9/16) patients had positive LMP1 expression while 44%
(7/16) had positive LMP2A expression. Moreover, LMP1
expression was obviously related to the presence of B
symptoms and patients’ survival status, while LMP2A
expression was related to gender and patients prognosis.
It is interesting to notice that high expression of both
proteins was correlated with poor prognosis. In addition,
LMP2A expression appears to be related to gender. Al-
though the relationship between LMP2A expression and
gender was significant, we need to confirm it in later
studies that enroll larger samples because only 3 female
Mao et al. Diagnostic Pathology 2012, 7:178 Page 7 of 8
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ciation was shown between LMP1 and LMP2A expres-
sion and other clinical parameters, including age, Ann
Arbor stage, LDH level, IPI or response to treatment.
Furthermore, Kaplan-Meier survival analysis showed
that positive B symptoms, single therapy strategy and
high expression of LMP1 and LMP2A could independ-
ently predict poor overall survival. These results are con-
sistent with the regulatory effects of LMP1 and LMP2A
on tumor cell growth, invasion, and metastasis reported
in previous studies [14-17], and the poor prognosis of
patients with high expression of LMP1 and LMP2A
[3,29].
However, due to small sample size of this study, fur-
ther studies that employ larger scale of clinical samples
of ENKTL will be important to confirm our findings,
which will provide the judgment on the values of LMP1
and LMP2A proteins for the diagnosis and prognosis of
ENKTL.
Conclusion
The expression of both LMP1 and LMP2A shows sig-
nificant correlations with the prognosis of patients with
ENKTL. LMP1 and LMP2A are novel prognostic mar-
kers of ENKTL.
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